PT1254663E - Agente antiviral - Google Patents

Agente antiviral

Info

Publication number
PT1254663E
PT1254663E PT01110873T PT01110873T PT1254663E PT 1254663 E PT1254663 E PT 1254663E PT 01110873 T PT01110873 T PT 01110873T PT 01110873 T PT01110873 T PT 01110873T PT 1254663 E PT1254663 E PT 1254663E
Authority
PT
Portugal
Prior art keywords
present
virus agent
virus
construct
gene encoding
Prior art date
Application number
PT01110873T
Other languages
English (en)
Inventor
Marina N Papuashvili
Original Assignee
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Ltd filed Critical Technologie Integrale Ltd
Publication of PT1254663E publication Critical patent/PT1254663E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT01110873T 2001-05-04 2001-05-04 Agente antiviral PT1254663E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/848,269 US20030176372A1 (en) 2001-05-04 2001-05-04 Anti-virus agent
EP01110873A EP1254663B1 (en) 2001-05-04 2001-05-04 Anti-virus agent

Publications (1)

Publication Number Publication Date
PT1254663E true PT1254663E (pt) 2005-04-29

Family

ID=46679311

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01110873T PT1254663E (pt) 2001-05-04 2001-05-04 Agente antiviral

Country Status (15)

Country Link
US (1) US20030176372A1 (pt)
EP (1) EP1254663B1 (pt)
JP (1) JP2005510455A (pt)
CN (1) CN1527716A (pt)
AT (1) ATE281838T1 (pt)
CA (1) CA2446204A1 (pt)
CZ (1) CZ20033288A3 (pt)
DE (1) DE60107052T2 (pt)
DK (1) DK1254663T3 (pt)
ES (1) ES2234730T3 (pt)
HU (1) HUP0400987A3 (pt)
IL (1) IL158739A0 (pt)
PL (1) PL367451A1 (pt)
PT (1) PT1254663E (pt)
WO (1) WO2002089817A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138580B1 (en) * 2007-04-20 2013-03-20 Takara Bio, Inc. Vector for gene therapy
JP6915870B2 (ja) * 2016-01-27 2021-08-04 国立大学法人北海道大学 ウイルスフリー植物体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973507A (en) * 1989-01-23 1990-11-27 Horian Richard C Thin wood laminate panel and method of fabrication
EP0479180A3 (en) * 1990-10-05 1992-08-26 Hoechst Aktiengesellschaft Virus resistant plants, method for their production

Also Published As

Publication number Publication date
HUP0400987A3 (en) 2004-10-28
WO2002089817A3 (en) 2003-01-30
WO2002089817A2 (en) 2002-11-14
IL158739A0 (en) 2004-05-12
EP1254663A1 (en) 2002-11-06
JP2005510455A (ja) 2005-04-21
CN1527716A (zh) 2004-09-08
EP1254663B1 (en) 2004-11-10
DE60107052T2 (de) 2005-11-24
DK1254663T3 (da) 2005-03-21
HUP0400987A2 (hu) 2004-08-30
US20030176372A1 (en) 2003-09-18
PL367451A1 (en) 2005-02-21
CZ20033288A3 (cs) 2004-04-14
ES2234730T3 (es) 2005-07-01
DE60107052D1 (de) 2004-12-16
CA2446204A1 (en) 2002-11-14
ATE281838T1 (de) 2004-11-15

Similar Documents

Publication Publication Date Title
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
EA200701450A1 (ru) РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
ES2086997T3 (es) Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
DK0784483T3 (da) Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
CA2210353A1 (en) Stabilized external guide sequences
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
DE69837708D1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
MXPA01010392A (es) Produccion de vacunas de virus con arn de hebra negativa atenuados a partir de secuencias de nucleotidos clonadas.
MXPA03000061A (es) Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos.
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
DE60331758D1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
ATE294866T1 (de) Zellen, die virus-resistent und von viren infizierbar sind
PT1254663E (pt) Agente antiviral
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
SE9804298D0 (sv) New medical use
EA200301089A1 (ru) Противовирусный агент
CA2379003A1 (en) Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides
BR9801992A (pt) Processos para a preparação de vìrus da doença de marek usando linhas celulares contìnuas de mamìfero.
ATE269064T1 (de) Impfstoffe gegen den hepatitis b und c virus
BR9903877A (pt) Composicões e métodos para a proteção de animais contra doença associada a lentivìrus, assim como o vìrus da imunodeficiência felina
CA2086577A1 (en) Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene